VEGFA and neoplasm: SRPIN340 preferentially inhibits SRPK1 and SRPK2, with a higher inhibitory effect on SRPK1, and was shown to reduce human melanoma tumor growth in vivo, but not in vitro, and was attributable to the regulation of VEGF expression and angiogenesis reduction (85).